Annual CFO
-$29.01 M
-$10.14 M-53.72%
30 September 2022
Summary:
NeuBase Therapeutics annual cash flow from operations is currently -$29.01 million, with the most recent change of -$10.14 million (-53.72%) on 30 September 2022. During the last 3 years, it has fallen by -$10.14 million (-53.72%).NBSE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$2.00 M
+$1.64 M+45.04%
30 September 2023
Summary:
NeuBase Therapeutics quarterly cash flow from operations is currently -$2.00 million, with the most recent change of +$1.64 million (+45.04%) on 30 September 2023.NBSE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$14.78 M
+$4.64 M+23.87%
30 September 2023
Summary:
NeuBase Therapeutics TTM cash flow from operations is currently -$14.78 million, with the most recent change of +$4.64 million (+23.87%) on 30 September 2023.NBSE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -53.7% | +63.2% | +21.7% |
| 5 y5 years | -919.6% | -235.5% | -419.5% |
NBSE Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | <-9999.0% | -786.1% | -4479.9% |
NeuBase Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$2.00 M(-45.0%) | -$14.78 M(-23.9%) |
| June 2023 | - | -$3.64 M(+5.7%) | -$19.42 M(-21.3%) |
| Mar 2023 | - | -$3.45 M(-39.4%) | -$24.69 M(-16.1%) |
| Dec 2022 | - | -$5.69 M(-14.3%) | -$29.43 M(+1.4%) |
| Sept 2022 | -$29.01 M(+53.7%) | -$6.64 M(-25.5%) | -$29.01 M(+4.3%) |
| June 2022 | - | -$8.91 M(+8.8%) | -$27.82 M(+11.1%) |
| Mar 2022 | - | -$8.19 M(+55.5%) | -$25.03 M(+22.9%) |
| Dec 2021 | - | -$5.27 M(-3.2%) | -$20.36 M(+7.9%) |
| Sept 2021 | -$18.87 M(+76.2%) | -$5.44 M(-11.2%) | -$18.87 M(+11.0%) |
| June 2021 | - | -$6.13 M(+74.1%) | -$17.00 M(+23.6%) |
| Mar 2021 | - | -$3.52 M(-6.9%) | -$13.75 M(+14.1%) |
| Dec 2020 | - | -$3.78 M(+6.0%) | -$12.05 M(+12.5%) |
| Sept 2020 | -$10.71 M(+276.4%) | -$3.57 M(+23.7%) | -$10.71 M(+38.4%) |
| June 2020 | - | -$2.89 M(+58.9%) | -$7.74 M(+39.2%) |
| Mar 2020 | - | -$1.82 M(-25.6%) | -$5.56 M(+17.8%) |
| Dec 2019 | - | -$2.44 M(+309.0%) | -$4.72 M(+65.9%) |
| Sept 2019 | -$2.85 M(-70.0%) | -$596.90 K(-15.3%) | -$2.85 M(+0.0%) |
| June 2019 | - | -$704.60 K(-27.9%) | -$2.85 M(-14.4%) |
| Mar 2019 | - | -$977.10 K(+72.4%) | -$3.32 M(-43.3%) |
| Dec 2018 | - | -$566.80 K(-5.0%) | -$5.86 M(-38.2%) |
| Sept 2018 | -$9.49 M(-50.8%) | -$596.60 K(-49.5%) | -$9.49 M(-33.0%) |
| June 2018 | - | -$1.18 M(-66.4%) | -$14.17 M(-17.2%) |
| Mar 2018 | - | -$3.52 M(-16.1%) | -$17.11 M(-2.6%) |
| Dec 2017 | - | -$4.20 M(-20.5%) | -$17.56 M(-9.0%) |
| Sept 2017 | -$19.29 M(+20.7%) | -$5.27 M(+28.1%) | -$19.29 M(+1.3%) |
| June 2017 | - | -$4.12 M(+3.8%) | -$19.05 M(-0.3%) |
| Mar 2017 | - | -$3.97 M(-33.1%) | -$19.11 M(+2.8%) |
| Dec 2016 | - | -$5.93 M(+17.8%) | -$18.59 M(+16.3%) |
| Sept 2016 | -$15.99 M(+49.5%) | -$5.03 M(+20.3%) | -$15.99 M(+21.5%) |
| June 2016 | - | -$4.18 M(+21.5%) | -$13.16 M(+23.5%) |
| Mar 2016 | - | -$3.44 M(+3.5%) | -$10.66 M(-5.5%) |
| Dec 2015 | - | -$3.33 M(+50.6%) | -$11.28 M(+5.5%) |
| Sept 2015 | -$10.69 M(+99.5%) | -$2.21 M(+31.7%) | -$10.69 M(+6.3%) |
| June 2015 | - | -$1.68 M(-58.8%) | -$10.06 M(-2.6%) |
| Mar 2015 | - | -$4.07 M(+48.6%) | -$10.33 M(+51.8%) |
| Dec 2014 | - | -$2.74 M(+73.6%) | -$6.81 M(+27.0%) |
| Sept 2014 | -$5.36 M | -$1.58 M(-19.0%) | -$5.36 M(+13.9%) |
| June 2014 | - | -$1.95 M(+258.6%) | -$4.71 M(+35.0%) |
| Mar 2014 | - | -$542.90 K(-58.0%) | -$3.49 M(+5.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | - | -$1.29 M(+39.8%) | -$3.32 M(+23.5%) |
| Sept 2013 | -$2.69 M(+53.4%) | -$924.40 K(+27.0%) | -$2.69 M(+17.7%) |
| June 2013 | - | -$727.90 K(+93.5%) | -$2.29 M(+15.3%) |
| Mar 2013 | - | -$376.20 K(-43.1%) | -$1.98 M(-9.5%) |
| Dec 2012 | - | -$661.10 K(+27.2%) | -$2.19 M(+24.9%) |
| Sept 2012 | -$1.75 M(+74.6%) | -$519.80 K(+22.4%) | -$1.75 M(+6.8%) |
| June 2012 | - | -$424.70 K(-27.4%) | -$1.64 M(+13.5%) |
| Mar 2012 | - | -$585.20 K(+161.0%) | -$1.45 M(+35.9%) |
| Dec 2011 | - | -$224.20 K(-45.2%) | -$1.07 M(+6.1%) |
| Sept 2011 | -$1.00 M(+92.5%) | -$408.80 K(+78.0%) | -$1.00 M(+33.7%) |
| June 2011 | - | -$229.60 K(+13.0%) | -$751.40 K(+19.1%) |
| Mar 2011 | - | -$203.10 K(+24.5%) | -$630.90 K(+15.1%) |
| Dec 2010 | - | -$163.10 K(+4.8%) | -$548.00 K(+5.0%) |
| Sept 2010 | -$521.80 K(+25.7%) | -$155.60 K(+42.6%) | -$521.70 K(+9.7%) |
| June 2010 | - | -$109.10 K(-9.2%) | -$475.70 K(-16.2%) |
| Mar 2010 | - | -$120.20 K(-12.1%) | -$567.70 K(+18.1%) |
| Dec 2009 | - | -$136.80 K(+24.8%) | -$480.70 K(+15.8%) |
| Sept 2009 | -$415.20 K(-20.1%) | -$109.60 K(-45.5%) | -$415.10 K(+27.7%) |
| June 2009 | - | -$201.10 K(+505.7%) | -$325.00 K(-26.1%) |
| Mar 2009 | - | -$33.20 K(-53.4%) | -$439.90 K(+8.2%) |
| Dec 2008 | - | -$71.20 K(+265.1%) | -$406.70 K(-21.7%) |
| Sept 2008 | -$519.50 K(-90.3%) | -$19.50 K(-93.8%) | -$519.50 K(+3.9%) |
| June 2008 | - | -$316.00 K(<-9900.0%) | -$500.00 K(+171.7%) |
| Mar 2008 | - | $0.00(-100.0%) | -$184.00 K(0.0%) |
| Dec 2007 | - | -$184.00 K(+4081.8%) | -$184.00 K(-67.8%) |
| Sept 2007 | -$5.36 M(+838.9%) | - | - |
| Dec 2006 | -$571.10 K(-368.4%) | -$4400.00(+120.0%) | -$571.10 K(+27.7%) |
| Sept 2006 | - | -$2000.00(-99.7%) | -$447.30 K(+191.6%) |
| June 2006 | - | -$680.50 K(-687.7%) | -$153.40 K(-169.5%) |
| Mar 2006 | - | $115.80 K(-3.0%) | $220.70 K(+3.7%) |
| Dec 2005 | $212.80 K(-6.5%) | $119.40 K(-59.1%) | $212.80 K(-1374.3%) |
| Sept 2005 | - | $291.90 K(-195.3%) | -$16.70 K(-92.9%) |
| June 2005 | - | -$306.40 K(-384.0%) | -$236.50 K(-223.8%) |
| Mar 2005 | - | $107.90 K(-198.0%) | $191.00 K(-16.0%) |
| Dec 2004 | $227.50 K(-1051.9%) | -$110.10 K(-252.7%) | $227.40 K(-32.6%) |
| Sept 2004 | - | $72.10 K(-40.5%) | $337.50 K(+27.2%) |
| June 2004 | - | $121.10 K(-16.1%) | $265.40 K(+83.9%) |
| Mar 2004 | - | $144.30 K | $144.30 K |
| Dec 2003 | -$23.90 K | - | - |
FAQ
- What is NeuBase Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for NeuBase Therapeutics?
- What is NeuBase Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for NeuBase Therapeutics?
What is NeuBase Therapeutics annual cash flow from operations?
The current annual CFO of NBSE is -$29.01 M
What is the all time high annual CFO for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual cash flow from operations is $227.50 K
What is NeuBase Therapeutics quarterly cash flow from operations?
The current quarterly CFO of NBSE is -$2.00 M
What is the all time high quarterly CFO for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly cash flow from operations is $291.90 K
What is NeuBase Therapeutics TTM cash flow from operations?
The current TTM CFO of NBSE is -$14.78 M
What is the all time high TTM CFO for NeuBase Therapeutics?
NeuBase Therapeutics all-time high TTM cash flow from operations is $337.50 K